Supporting, developing and meeting people’s needs and rights speaks to the core intention of our work with, and for, people – our colleagues, our patients, healthcare professionals, and all those whose lives we affect, directly or indirectly, in our working community. This ambition is underwritten by our Philosophy that ‘People Come First at Ferring’.

See more of our People activities.

Within the business, we aim to provide a safe, healthy and supportive environment for our colleagues, one that encourages performance and pride. At the same time, we seek to provide the right kind of support (whether training, financial or medical) to our patients and the network of healthcare partners around them.

‘A key aspect of CSR is its contribution
 to building Ferring’s employer brand 
identity… for attracting talent and
keeping good people.. our CSR
Ambassadors are a vital part of that.’

Lydia Chua, Senior HR Director,
Asia Pacific

© Joni Kabana, Kabana Photography

Our Progress

Policies and Practices

We have a comprehensive set of policies and processes designed to enable and support colleagues’ journeys through Ferring wherever they are around the world. Some highlights:

  • A new Ferring Philosophy global training programme “Leading with Integrity”, was rolled out at manager levels across the business in 2017.
  • In Asia Pacific our employee-run welfare committees and CSR committees organise employee engagement activities to foster a sense of team spirit and collaboration (e.g. fun runs, movies, annual dinners etc).
  • Flexible working arrangements are now increasingly core to how we work, supported by improvements in supporting technologies which make telecommuting more accessible.
  • Ferring Pharmaceuticals Russia was awarded the Aon Hewitt Best Employer of Russia 2017. The business showed 92% levels of engagement and a participation rate of 97%. The Aon Global Best Employers’ programme recognises achievements that demonstrate excellence in the workplace.


Selection of our initiatives

Combating maternal death 

Excessive bleeding after childbirth, known as postpartum haemorrhage (PPH), is the leading cause of maternal death. Each year, more than 80,000 women die from PPH. Oxytocin is currently recommended as the standard of care for preventing PPH. However, it must be stored and transported at 2-8 degrees Celsius which is difficult to maintain in many countries, meaning many women do not have access to this lifesaving drug and, when they do, its quality may be degraded due to heat exposure.

Together with its partners MSD for Mothers and the World Health Organization (WHO), Ferring is collaborating on the world’s largest clinical trial in maternal health. CHAMPION has enrolled approximately 30,000 women from across 10 countries to compare the effectiveness and safety of Ferring’s medicine, heatstable carbetocin, to oxytocin, in the prevention of PPH.

Our goal is to make PPH history. If positive results are secured from the trial, Ferring will seek to obtain registrations and manufacture this treatment for the public sector of low and lower-middle-income countries that have a high burden of maternal deaths. This will be on a non-profit basis at an affordable and sustainable access price. In doing so, we aim to play our part in supporting the UN Sustainable Development Goal (SDG) 3: Ensure healthy lives and promote wellbeing for all at all ages.


Next generation gastroenterologists

Our Czech Republic office has been supporting the Kasafirek Prize for the last six years. It supports a long-term educational programme for young gastroenterologists and endoscopists and is awarded for the best professional article on gastroenterology or endoscopy published in a leading international gastroenterology journal. Candidates nominate their articles annually and the expert committee (on which Ferring sits) decides on the winner. The Award-winner receives €2,000 during the opening ceremony of the largest global gastroenterology congress. We see this project as an example of our desire to support young physicians, our future opinion leaders in the sector, and encourage their global recognition.


Fertility research collaboration 

Ferring is a core member of ReproUnion, a network of 13 clinical and research units across Denmark and Sweden designed to foster research and clinical collaboration across disciplines and geographical borders in fertility. Central to its philosophy is the desire to optimise the treatment of patients. By combining expertise from different centres, patients can be referred to the right specialist in Sweden or in Denmark. Up to six colleagues from our Therapeutic and Clinical teams in Copenhagen are involved. Since our involvement began in 2015, between 200-300 academics/ clinicians have been reached, more than 1,000 patients assisted, and up to 10,000 members of the wider global scientific community reached via publications. Ferring has contributed EUR 1.5 million to a total collaborative budget of EUR 13.5 million.


Global Challenge – Body & mind fitness 

In the fourth year of Ferring’s participation in the Global Challenge, almost 1,600 employees took 10,000 steps a day during a 100 day virtual journey around the world. Ferring China topped the team leader board with an impressive average of 25,000 steps per day. Together, Ferring teams have walked a distance equivalent to 30 circumnavigations around earth. The 100-day Global Challenge encourages employees to bike, walk, run, and swim to improve overall health and wellbeing – and have fun! The Challenge also offers tips on nutrition and a healthy mind-set. This year’s results prove the benefits, with 50% claiming to feel more productive and 70% less stressed.


Top and bottom photos courtesy of Jone Kabana,Kabana Photography